Description
Overview
KPV (Lys-Pro-Val) is a naturally occurring tripeptide, the C-terminal fragment of alpha-MSH (alpha-melanocyte stimulating hormone). It's bioidentical, produced endogenously as an anti-inflammatory regulator. KPV directly inhibits NF-κB, reducing IL-1, IL-6, and TNF-alpha. Its mechanism is well-characterized in human intestinal cell lines: it enters inflamed gut epithelium via the PepT1 transporter (which is upregulated in IBD), making oral delivery especially targeted in colitis. Preclinical models consistently show colitis improvement. Human RCTs have not been conducted. Unlike many peptides, KPV does not cause melanogenic (tanning) effects due to lacking the N-terminal α-MSH sequence.
Structure & Chemistry
- Molecular formula: C₁₆H₃₀N₄O₄
- Category: ANTI-INFLAMMATORY / GUT HEALING
- Molecular size: 342.43 Da (Lys-Pro-Val tripeptide)
Regulatory & Research Status
- NO HUMAN CLINICAL TRIALS: All IBD and skin benefits are from animal models and human cell studies (in vitro); no published human RCTs.
- FDA: Not approved for any indication; available through research/compounding channels.
- BIOIDENTICAL: KPV is the C-terminal tripeptide of endogenous α-MSH, strong mechanistic rationale for safety.
- DOSING: Practitioner-derived protocols only; no clinical dose-finding studies in humans.
- CANCER NOTE: KPV shows antitumorigenic potential in colitis-associated cancer mouse models via PepT1 pathway, no human data.
Specifications
| Presentation | 10mg single vial |
|---|---|
| Purity | >99% by HPLC |
| Form | Lyophilized powder (reconstitute with bacteriostatic water for laboratory use) |
| Category | ANTI-INFLAMMATORY / GUT HEALING |
For laboratory and research use only. Not for human or animal consumption. Not approved by the FDA for any therapeutic use. No claims regarding therapeutic efficacy are made or implied. Must be 21 or older.
Reviews
There are no reviews yet.